This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Medbox Shares Tumble On Fresh Accounting Concerns

Stocks in this article: MDBX

NEW YORK (TheStreet) --Medbox MDBX, a controversial maker of medical marijuana vending machines that trades on the off-exchange OTCPink marketplace, saw shares fall more than 6% Tuesday after a report accused the company of "MULTIPLE FRAUDS" [the caps are from the report] and a law firm cited the report in announcing an investigation of Medbox.

Medbox shares lost 6.14% Tuesday to close at $30, according to the Web site of OTCMarkets, which operates the OTCPink marketplace. The shares bounced between $26.37 and $33.24 on the day. 

The 13-page report was from a company called Citron Research, which says it is in its "13th year of publishing investigative research into suspect publicly traded companies." Citron claims it "has exposed more corporate fraud than any other source on Wall Street."

After citing a previous report on Medbox from the Southern Investigative Reporting Foundation, which pointed to irregularities in Medbox corporate filings, the Citron report pointed to several new red flags. For example, on Nov. 19, Medbox reported a profit for the quarter ended Sept. 30 in a filing with OTCMarkets. However, a Jan. 21 filing with the Securities and Exchange Commission covering the same period shows Medbox is losing money, Citron claims.

The Citron report was published Tuesday morning. Tuesday afternoon, Johnson & Weaver, a law firm, issued a press release citing the Citron report and saying it would investigate.

Medbox followed up with a press release of its own, stating it "discovered some errors in accounting which we have since corrected in the latest financials."

Medbox has not yet responded to TheStreet's request for comment on this story.

Follow @dan_freed

Related: Medbox CEO Weighs in on Marijuana Stocks.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,077.44 +47.23 0.26%
S&P 500 2,090.70 +8.82 0.42%
NASDAQ 4,801.0410 +27.5690 0.58%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs